R-2-hydroxyglutarate as the key effector of IDH mutations promoting oncogenesis

Dan Ye; Shenghong Ma; Yue Xiong; Kun-Liang Guan

doi:10.1016/j.ccr.2013.03.005

R-2-hydroxyglutarate as the key effector of IDH mutations promoting oncogenesis

Cancer Cell. 2013 Mar 18;23(3):274-6. doi: 10.1016/j.ccr.2013.03.005.

Authors

Dan Ye¹, Shenghong Ma, Yue Xiong, Kun-Liang Guan

Affiliation

¹ Key Laboratory of Molecular Medicine of Ministry of Education and Institutes of Biomedical Sciences, Shanghai Medical College, College of Life Science, Fudan University, Shanghai 200032, China.

Abstract

The tumor-associated isocitrate dehydrogenase (IDH) mutants are unique in that they have lost their normal catalytic activity and gained a novel function to produce R-2-hydroxyglutarate (R-2-HG). A recent study now shows that R-2-HG can reversibly promote leukemogenesis in vitro, suggesting a therapeutic potential of targeting mutant IDH1 and IDH2.

Publication types

Comment

Abstract

Publication types

Grants and funding